Tricom-cea (** Investigational - no approved brand names (various clinical trial designations) **)

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Tricom-cea is an investigational vaccine therapy being studied in clinical trials for certain types of advanced or metastatic cancers, including colorectal cancer, that express the CEA (carcinoembryonic antigen) protein. It is designed to stimulate the patient's own immune system to target and attack cancer cells. The therapy involves harvesting a patient's own dendritic cells (a type of immune cell), modifying them in a lab to include CEA, and then re-infusing them back into the patient. This process aims to teach the immune system to recognize and fight cancer cells that have CEA on their surface. It is currently in early-phase trials to determine its safety, how well it can be tolerated, and if it can trigger an immune response against cancer. It is not yet an approved treatment for colorectal cancer.

Mechanism of Action

Tricom-cea is a type of cancer vaccine. It works by using a patient's own dendritic cells. These cells are modified in the lab to display CEA (a protein often found on colorectal cancer cells). When these modified cells are given back to the patient, they act like teachers, showing the immune system what CEA looks like. This helps the immune system, specifically T-cells, learn to recognize and attack cancer cells that have CEA on their surface. The vaccine uses a fowlpox virus vector to deliver the CEA information to the dendritic cells.

Side Effects

As Tricom-cea is an investigational therapy in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. In the Phase 1 trial (NCT00027534) The primary focus was on safety and determining the maximum tolerated dose. Side effects observed in that trial included local reactions at the injection site (like redness Swelling Pain) and flu-like symptoms (like fever Chills Fatigue). More comprehensive data on side effects is expected as trials continue.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00027534 Phase 1
Archived
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
United States

Quick Info

Brand Name** Investigational - no approved brand names (various clinical trial designations) **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.